MedPath

Hemodialysis and Erythrocyte Fatty-Acid Status: a Lipidomics Study

Not Applicable
Completed
Conditions
Lipidomics
Fatty Acid Metabolism
Erythrocytes
Hemodialysis
Interventions
Other: Blood sampling
Registration Number
NCT03857984
Lead Sponsor
Benjamin Gollasch
Brief Summary

Hypotension with potentially serious consequences for organ perfusion is a common complication in extracorporeal procedures such as hemodialysis / hemofiltration. The exact reasons for this are still insufficiently clarified. Probably periinterventional vasorelaxant released substances play a crucial role in these procedures. These substances could be due to contact of blood cells with the Membrane in the dialyzer / hemofilter arise. In this project the hypothesis will be checked, if EETs / DHETs are released by Erythrocytes during hemodialysis and thus act as potential candidate products for the result of hypotonic phases in the Dialysis.

We will determine differences in RBC fatty acids profiling in hemodialysis patients before and after dialysis intervention. Furthermore a matched control group of healthy individuals will be profiled. RBC fatty acids profiling will be achieved by using targeted HPLC-MS mass spectrometry.

It is believed that during hemodialysis / HLM / CVVH there is an increase in EETs / DHETs in the serum and in the erythrocytes. It is believed that shear forces play an important role in the release of erythrocyte EETs / DHETs.

Detailed Description

Differences in Erythrocyte Fatty-Acid Status Profiling in:

* before and after hemodialysis intervention

* in hemodialysis patients and healthy individuals Venous blood will be collected from each subject in the sitting position

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Erythrocyte Fatty-Acid StatusBlood samplingErythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
Primary Outcome Measures
NameTimeMethod
Coefficient of variation of relative quantities of erythrocyte fatty-acid parameters related to its dynamic during Hemodialysis, using LC-MS / MS.4-5 Months

EETs / DHETs will be analyzed in the erythrocytes and serum of the recovered blood samples.

The determination will made in cooperation with a Berliner Biotech company. This involves liquid chromatography with MS coupling (LC-MS / MS) used. The data analysis is carried out by means of suitable statistical methods to perform erythrocyte fatty-acid status profiling.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Charité University Experimental & Clinical Research Center

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath